Gerwin Huls

Head of department

University Medical Center Groningen
Country flagNetherlands
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

In pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. In this study, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 nontransplanted controls. CH was detected in 16% of HCT recipients and 8% of controls at variant allele frequencies of 0.01 to 0.31. Mutations were predominantly in DNMT3A (80%) and TET2 (20%). Older hematopoietic age (OR: 1.07; P P = 0.02) independently increased the risk of CH, indicating both aging- and transplantation-induced effects. Large clones (variant allele frequency >0.10) were found exclusively in HCT recipients. Notably, CH was also detected within 15 years after a cord blood HCT. Inflammatory processes around graft infusion were associated with CH presence. Future studies are required to track the evolution of posttransplant CH and its impact on future cardiovascular diseases, second malignancies, and overall survival. Significance: As survival of HCT recipients continues to improve, late treatment effects gain importance. We demonstrate that pediatric HCT recipients show increased risk of CH compared with age-matched controls. Prospective studies are crucial to understand the clinical implications of posttransplant CH in this young population.

Year:

2025

Introduction Enteropathy‐associated T‐cell lymphoma (EATL) is a peripheral T‐cell lymphoma (PTCL) with a poor prognosis. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide consolidated by autologous stem cell transplantation (ASCT) are recommended for fit PTCL patients. The role of etoposide and ASCT in EATL is unclear. Methods This study reports the incidence, treatment, and outcome of EATL patients using the Netherlands Cancer Registry, with nationwide coverage of >95%. Results All patients diagnosed in 1989–2021 ( n = 351, 77% treated) were identified (median age 67 years, 56% male, 50% limited stage). Time period analysis assessed trends in primary therapy and overall survival (OS). Treatment included chemotherapy (CT) (34%), surgery (18%), surgery and CT (19%) or CT followed by ASCT (7%). The 5‐year OS for treated patients with limited versus advanced stage was 19% and 9% respectively. The 2‐year OS improved over time (21%–33%, p = 0.06). Surgery only (hazard ratio [HR] 2.16; 95% confidence interval [CI] 1.55–3.01, p < 0.01) and advanced‐stage disease (HR 1.67; 95% CI 1.25–2.23, p = 0.01) were predictors of poor prognosis. ASCT (HR 0.31; 95% CI 0.18–0.56) was associated with improved OS. Conclusion There was no statistical difference in OS between patients treated with or without etoposide. Current first‐line treatment is ineffective.

Year:

2024

Dependency on mitochondrial oxidative phosphorylation (OxPhos) is a potential weakness for leukemic stem cells (LSCs) that can be exploited for therapeutic purposes. Fatty acid oxidation (FAO) is a crucial OxPhos-fueling catabolic pathway for some acute myeloid leukemia (AML) cells, particularly chemotherapy-resistant AML cells. Here, we identified cold sensitivity at 4°C (cold killing challenge; CKC4), commonly used for sample storage, as a novel vulnerability that selectively kills AML LSCs with active FAO-supported OxPhos while sparing normal hematopoietic stem cells (HSCs). Cell death of OxPhos-positive leukemic cells was induced by membrane permeabilization at 4°C; by sharp contrast, leukemic cells relying on glycolysis were resistant. Forcing glycolytic cells to activate OxPhos metabolism sensitized them to CKC4. Lipidomic and proteomic analyzes showed that OxPhos shapes the composition of the plasma membrane and introduces variation of 22 lipid subfamilies between cold-sensitive and cold-resistant cells. Together, these findings indicate that steady-state energy metabolism at body temperature predetermines the sensitivity of AML LSCs to cold temperature, suggesting that cold sensitivity could be a potential OxPhos biomarker. These results could have important implications for designing experiments for AML research to avoid cell storage at 4°C.

Year:

2024

Pemphigus vulgaris (PV) is a rare autoimmune bullous disease characterized by blistering of the skin and mucosa owing to the presence of autoantibodies against the desmosome proteins desmoglein 3 and occasionally in conjunction with desmoglein 1. Fundamental research into the pathogenesis of PV has revolutionized its treatment and outcome with rituximab, a B-cell-depleting therapy. The critical contribution of B cells to the pathogenesis of pemphigus is well accepted. However, the exact pathomechanism, mechanisms of onset, disease course and relapse remain unclear. In this narrative review, we provide an overview of the fundamental research progress that has unfolded over the past few centuries to give rise to current and emerging therapies. Furthermore, we summarize the multifaceted roles of B cells in PV, including their development, maturation and antibody activity. Finally, we explored how these various aspects of B-cell function contribute to disease pathogenesis and pave the way for innovative therapeutic interventions.

Year:

2024

Collaborators (20)

Jeroen Bremer

University Medical Center Groningen

NETHERLANDS
View details

Jean-Emmanuel Sarry

Principal Investigator

INSERM Délégation régionale Midi-Pyrenees Limousin

FRANCE
View details

Johanna Chiche

Université Côte d'Azur

FRANCE
View details

Anne P. J. de Pagter

Erasmus MC

NETHERLANDS
View details

Jean-François Peyron

Université Côte d'Azur

FRANCE
View details

marc bierings

MD PHD Chief

Princess Maxima Center

NETHERLANDS
View details

Stefan Nierkens

Medical Immunologist

Princess Maxima Center

NETHERLANDS
View details

Leontien Kremer

Principle Investigator & Professor Survivorship Childhood Cancer

Prinses Máxima Centrum voor Kinderoncologie

NETHERLANDS
View details

F. J. Sherida H. Woei‐A‐Jin

University Hospitals Leuven

BELGIUM
View details

Véronique De Mas

Institut Universitaire du Cancer de Toulouse

FRANCE
View details

Marie José Kersten

University of Amsterdam

NETHERLANDS
View details

Peter Heeringa

Scientific Staff

University Medical Center Groningen

NETHERLANDS
View details

Delphine Debayle

Institute of Pharmacology

FRANCE
View details

Saskia Haitjema

Associate professor

Utrecht University

NETHERLANDS
View details

Marcel Nijland

University Medical Center Groningen

NETHERLANDS
View details

Joost Vermaat

Leiden University Medical Center

NETHERLANDS
View details

A. Gostyński

Maastricht University Medical Centre

NETHERLANDS
View details

Mirjam Belderbos

Principal Investigator

Princess Máxima Center for Pediatric Oncology

NETHERLANDS
View details

Arjan Lankester

Head Program Pediatric Stem Cell Transplantation

Leiden University Medical Center

NETHERLANDS
View details

Jan Jacob Schuringa

full professor

University Medical Center Groningen

NETHERLANDS
View details